Based on these results, we performed viability assays with six pancreatic adenocarcinoma human cell lines (PDAC) harbouring different oncogenic KRAS mutations and with a non-transformed cell line, all of them epithelial. The gene discussed is KRAS; the disease is pancreatic adenocarcinoma.